Program
debamestrocel
Also written as “Debamestrocel - MSC-NTF (NurOwn)”, “Nurown MSC-NTF cells” and “NurOwn® (MSC-NTF cells)”.
Its studies are mostly in Amyotrophic Lateral Sclerosis · Multiple Sclerosis, Chronic Progressive, led by Brainstorm-Cell Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Brainstorm-Cell Therapeutics | 41 open or running | phase 3since Aug 29, 2017 | Dec 17, 2013 | Nov 1, 2028phase 3 · NCT06973629 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 17, 2013First study: phase 2 study in Amyotrophic Lateral SclerosisFirst studyNCT02017912 · 48 enrolled · United States
- Aug 29, 2017Phase 3 study in Amyotrophic Lateral SclerosisNCT03280056 · 196 enrolled · United States
- Jan 7, 2019Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT03799718 · 23 enrolled · United States
- May 5, 2025Phase 3 study in Amyotrophic Lateral SclerosisNCT06973629 · 200 planned · United States
Ahead
- Nov 1, 2028Primary completion: phase 3 study in Amyotrophic Lateral SclerosisNCT06973629
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06973629Amyotrophic Lateral Sclerosis · United States | 3 | Not yet recruiting | Nov 1, 2028 | 200 |
| NCT03799718Multiple Sclerosis, Chronic Progressive · United States | 2 | Completed | Mar 11, 2021 | 23 |
| NCT03280056Amyotrophic Lateral Sclerosis · United States | 3 | Completed | Sep 29, 2020 | 196 |
| NCT02017912Amyotrophic Lateral Sclerosis · United States | 2 | Completed | Mar 2016 | 48 |
How it is read
Names in the registry
- “Debamestrocel - MSC-NTF (NurOwn)”, 1 entry
- “Nurown MSC-NTF cells”, 1 entry
- “NurOwn® (MSC-NTF cells)”, 1 entry
- “NurOwn (MSC-NTF cells)”, 1 entry
Conditions, from the studies’ own filings
- Amyotrophic Lateral Sclerosis, 3 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.